Left-Sided Pseudomonas Infective Endocarditis Presenting with Septic Shock and Ischemic Stroke in a Non-Injection Drug User Receiving PD-L1 Inhibitor Therapy
Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine
Infective endocarditis fromis a rare but serious infection with high morbidity and mortality. We report the case of a 66-year-old female with small cell lung cancer and no history of injection drug use or structural heart disease who developed left-sided infective endocarditis from. Her risk factors for this severe infection included healthcare exposure, a central venous catheter, malignancy, and recent PD-L1 inhibitor therapy with durvalumab. She was ultimately deemed not a surgical candidate and, given her poor prognosis, her family elected for discharge to home hospice with palliative therapy. This case highlights the high morbidity ofendocarditis despite combination antipseudomonal antibiotics and the shifting epidemiology ofendocarditis to left-sided infection in non-injection drug users with complex comorbidities, affecting surgical candidacy. We also discuss whether immunotherapy may represent an additional, hypothesis-generating risk factor for serious infections such asendocarditis.
